Efficacy Results announced: global first Antibody Mediated Prevention (AMP) trials

Most advanced clinical trials testing broadly neutralizing antibody against HIV demonstrate efficacy against sensitive strains.   The proof-of-concept AMP studies demonstrated that a broadly neutralizing antibody (bnAb) called VRC01 was effective at preventing the acquisition of HIV strains that were sensitive to the bnAb. This was assessed by a laboratory test that measures a virus’…